Triple-negative breast cancer: Epidemiological considerations and recommendations

Annals of Oncology

Volumn 23, Issue SUPPL. 6, 2012, Pages

  Boyle, P ^a  

^a INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

Biology; Breast cancer; Epidemiology; Triple negative

Indexed keywords

BRCA1 PROTEIN; COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR;

ADULT; AFRICAN; AFRICAN AMERICAN; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ETHNICITY; FAMILY HISTORY; FEMALE; GENE MUTATION; HISPANIC; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENARCHE; MICROARRAY ANALYSIS; MITOSIS INDEX; NULLIPARA; OBESITY; ORAL CONTRACEPTION; PREGNANCY; PREMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER;

EID: 84867123853     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds187     Document Type: Article

References (44)

1. Boyle P. The globalisation of cancer. Lancet 2006; 368: 629-630.
2. Boyle P, Levin B (eds). World Cancer Report 2008. Lyon: IARC 2008.
3. Autier P, Boniol M, La Vecchia C et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. Br Med J 2010; 341: c3620.
4. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumour characteristics among United States women. Breast Cancer Res 2007; 9: R28.
5. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896; 148: b104-b107.
6. Nielsen TO, Hsu FD, Jensen K et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
7. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
8. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
9. Bertucci F, Finetti P, Cervera N et al. How basal are triple-negative breast cancers? Int J Cancer 2008; 123: 236-240.
10. Bidard FC, Conforti R, Boulet T et al. Does triple-negative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple-negative' breast cancers. Ann Oncol 2007; 18: 1285-1286.
11. Vona-Davis L, Rose DP, Hazard H et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev 2008; 17: 3319-3324.
12. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502.
13. Rakha EA, El-Rehim DA, Paish C et al. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 2006; 42: 3149-3156.
14. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
15. Brown M, Tsodikov A, Bauer KR et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptornegative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer 2008; 112: 737-747.
16. Carey LA, Dees EC, Sawyer L et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
17. Cheang MC, Voduc D, Bajdik C et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-1376.
18. Lund MJ, Trivers KF, Porter PL et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009; 113: 357-370.
19. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
20. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
21. Sørlie T, Perou CM, Fan C et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 2006; 5: 2914-2918.
22. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
23. Sørlie T, Wang Y, Xiao C et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006; 7: 127.
24. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
25. Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer 2009; 9(Suppl 2): S73-S81.
26. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: a review. Pathology 2009; 41: 40-47.
27. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study hrom the California Cancer Registry. Cancer 2007; 109: 1721-1728.
28. Stead LA, Lash TL, Sobieraj JE et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009; 11: R18.
29. Kwan ML, Kushi LH, Weltzien E et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009; 11: R31.
30. Kurian AW, Fish K, Shema SJ et al. Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 2010; 12: R99.
31. Amirikia KC, Mills P, Bush J et al. Higher population-based incidence rates of triple-negative breast cancer among young African-American women: implications for breast cancer screening recommendations. Cancer 2011; 117: 2747-2753.
32. Huo D, Ikpatt F, Khramtsov A et al. Population differences in breast cancer: survey in indigenous african women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009; 27: 4515-4521.
33. Stark A, Kleer CG, Martin I et al. African ancestry and higher prevalence of triple-negative breast cancer: findings from an international study. Cancer 2010; 116: 4926-4932.
34. Lakhani SR, Van De Vijver MJ, Jacquemier J et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 2002; 20: 2310-2318.
35. Vona-Davis L, Rose DP, Hazard H et al. Triple-negative breast cancer and obesity in a rural appalachian population. Cancer Epidemiol Biomarkers Prev 2008; 17: 3319-3324.
36. Trivers KF, Lund MJ, Porter PL et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20: 1071-1082.
37. Shinde SS, Forman MR, Kuerer HM et al. Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 2010; 116: 4933-4943.
38. Dolle JM, Daling JR, White E et al. Risk factors for triple-negative breast cancer in women under age 45. Cancer Epidemiol Biomarkers Prev 2009; 18: 1157-1166.
39. Phipps AI, Chlebowski RT, Prentice R et al. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 2011; 103: 470-477.
40. Kabat GC, Kim M, Phipps AI et al. Smoking and alcohol consumption in relation to risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes Control 2011; 22: 775-783.
41. Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res 2010; 12 (Suppl 4): S8.
42. Bedard P, Salgado R, Singhal SK et al. Use of meta-analysis of gene expression profiling studies to identify biologically relevant pathways associated with aggressive breast cancer (BC) in young women. J Clin Oncol 2010; 28: 15s: Abstr 520.
43. Lim E, Vaillant F, Wu D et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009; 15: 907-913.
44. Prat A, Perou CM. Mammary development meets cancer genomics. Nat Med 2009; 15: 842-844.